New evidence suggests that second-line treatment with ramucirumab after first-line chemotherapy may lead to longer survival in people with pleural mesothelioma. Researchers in Italy recently published results of a double-blind, placebo-controlled trial of the drug. Ramucirumab inhibits a protein mesothelioma tumors need to form new blood vessels. The study included 161 pleural mesothelioma patients from across Italy. Researchers gave half of them second-line treatment with ramucirumab and another drug called gemcitabine. The other half had second-line treatment with gemcitabine alone. Results showed the ramucirumab group lived more than six months longer than those who got only gemcitabine. Few Options for Recurrent Mesothelioma Pleural mesothelioma is an aggressive cancer with few good treatment options. Most patients start with chemotherapy with Alimta….